COO

AI Memo

Cooper Companies

As of 2026-08-10/Confidence high

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-08-10 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

high

Horizon

—

Key catalyst

Q3 FY2026 earnings and outlook update • 2026-09-09

Base target: $81 / p=55% prob

Biggest risk

GAAP EPS was negative because of the litigation charge, Asia-Pacific CooperVision revenue declined organically, and tariffs and residual legal or strategic-review uncertainty could pressure results. Forward guidance and post-print estimate revisions are not available in the packet.

Invalidation

Break below $62 or thesis failure.

What would change my mind?

Record Q2 revenue, double-digit toric and multifocal growth, organic growth in both business units, margin expansion, and litigation de-risking support a constructive medium-term view. [#SEC-8K-2026-06-04]

Research note

Recommendation

—

Confidence

high

As of

2026-08-10

Base target

$81

p=55%

Bull target

$90

p=25%

Bear target

$62

p=20%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Q2 operating momentum remains a support
Recall-litigation overhang may continue to de-risk
Organic growth and margin execution

BearKey bullets

CooperVision Asia-Pacific revenue declined 6% organically in Q2 FY2026.
[#SEC-8K-2026-06-04]
Q3 execution, forward outlook, and analyst estimate revisions remain unconfirmed.

WatchKey bullets

Q3 FY2026 earnings and outlook update

Summary

High-level snapshot

Recommendation

Model confidence

high

Timeframe

Asset

Equity

Trigger

Base case: $81 (p=55%)

Target spread vs base: +11% / -23%

Scenario probabilities

Bull Target: $90 (p=25%)Base Target: $81 (p=55%)Bear Target: $62 (p=20%)

Commentary

Recent coverage is broadly constructive around record Q2 revenue and earnings, while the litigation charge remains the principal counterweight. Social, options, short-interest, and employee-sentiment data are unavailable; the Q3 event is scheduled, but forward revision evidence is limited.

As of 2026-08-10 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Q2 operating momentum remains a support
Recall-litigation overhang may continue to de-risk
Organic growth and margin execution

Scenarios

Bull Target (Scenario probability)

$90 / p=25% prob

Base Target (Scenario probability)

$81 / p=55% prob

Bear Target (Scenario probability)

$62 / p=20% prob

Analysis 2026-08-10 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.62

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-09-09
Q3 FY2026 earnings and outlook update
The company announced that it will report Q3 FY2026 results on September 9, 2026, followed by a conference call discussing results and current corporate developments. [#PR-EARNINGS-2026-07-30]
Prob 95.00% • Move 5.00% • Priced-in 55.00%

Short-term Catalysts

Next few weeks

Q2 operating momentum remains a support
2026-08-10
Q2 FY2026 revenue reached $1.082 billion, up 8% reported and 5% organically; non-GAAP EPS rose 26% to $1.21, and management cited a tenth consecutive quarter above consensus. [#SEC-8K-2026-06-04]
Prob 75% • Move 4% • Priced-in 70%
Recall-litigation overhang may continue to de-risk
2026-08-31
CooperSurgical reached agreements intended to resolve substantially all outstanding recall-related claims, although Q2 included a $271.6 million litigation charge. [#SEC-8K-2026-06-04]
Prob 65% • Move 3% • Priced-in 55%

Long-term Catalysts

Months to a year

Organic growth and margin execution
2026-12-31
Management cited new product launches, favorable demand drivers, operational discipline, and reorganization synergies; Q2 non-GAAP operating margin expanded to 27%. [#SEC-8K-2026-06-04]
Prob 65% • Move 10% • Priced-in 45%

Risks

CooperVision Asia-Pacific revenue declined 6% organically in Q2 FY2026. [#SEC-8K-2026-06-04]
Q3 execution, forward outlook, and analyst estimate revisions remain unconfirmed.
Recall-related litigation and defense costs may remain volatile despite agreements to resolve substantially all outstanding claims. [#SEC-8K-2026-06-04]
Tariffs and other cost pressures could offset operating gains.

Peers

Symbol	Summary
ABT	Broad diversified health-care reference; useful for sector context but not a clean CooperVision/CooperSurgical comparable.
BSX	Large medical-device reference with stronger cardiovascular exposure; peer read-through is limited without packet-level valuation or operating comparisons.
EW	Medtech reference with procedure-driven exposure; relevant sector context but only a loose direct peer for Cooper's businesses.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-08-10

Loading AI feed…

Symbol

Summary

ABT

Broad diversified health-care reference; useful for sector context but not a clean CooperVision/CooperSurgical comparable.

BSX

Large medical-device reference with stronger cardiovascular exposure; peer read-through is limited without packet-level valuation or operating comparisons.

Medtech reference with procedure-driven exposure; relevant sector context but only a loose direct peer for Cooper's businesses.